- Report
- March 2026
- 246 Pages
India
From €4350EUR$4,850USD£3,760GBP
- Report
- March 2026
- 178 Pages
China
From €4350EUR$4,850USD£3,760GBP
- Report
- March 2026
- 212 Pages
Germany
From €4350EUR$4,850USD£3,760GBP
- Report
- February 2026
- 173 Pages
Canada
From €4350EUR$4,850USD£3,760GBP
- Report
- February 2026
- 182 Pages
China
From €4350EUR$4,850USD£3,760GBP
- Report
- February 2026
- 174 Pages
Germany
From €4350EUR$4,850USD£3,760GBP
- Report
- February 2026
- 175 Pages
India
From €4350EUR$4,850USD£3,760GBP
- Report
- April 2025
- 150 Pages
Global
From €4350EUR$4,850USD£3,760GBP
- Report
- April 2025
- 150 Pages
Global
From €4350EUR$4,850USD£3,760GBP
- Report
- April 2025
- 150 Pages
Global
From €4350EUR$4,850USD£3,760GBP
- Report
- March 2025
- 150 Pages
Global
From €4350EUR$4,850USD£3,760GBP
- Report
- March 2025
- 150 Pages
Global
From €4350EUR$4,850USD£3,760GBP
- Report
- March 2025
- 150 Pages
Global
From €4350EUR$4,850USD£3,760GBP
- Report
- December 2024
- 150 Pages
Global
From €4350EUR$4,850USD£3,760GBP
- Report
- September 2023
- 266 Pages
Global
From €3229EUR$3,600USD£2,791GBP
- Report
- September 2023
- 129 Pages
Asia Pacific
From €1345EUR$1,500USD£1,163GBP
- Report
- July 2023
- 284 Pages
Global
From €3229EUR$3,600USD£2,791GBP
- Report
- July 2023
- 145 Pages
Europe
From €1345EUR$1,500USD£1,163GBP
- Report
- January 2025
- 270 Pages
Global
From €4480EUR$4,995USD£3,872GBP
- Report
- March 2025
- 94 Pages
Global
From €3500EUR$4,180USD£3,131GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more